List of Excipients in Branded Drug SPRAVATO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Pharmaceuticals Inc	SPRAVATO	esketamine hydrochloride	50458-028	CITRIC ACID MONOHYDRATE	2028-01-17
Janssen Pharmaceuticals Inc	SPRAVATO	esketamine hydrochloride	50458-028	EDETATE DISODIUM	2028-01-17
Janssen Pharmaceuticals Inc	SPRAVATO	esketamine hydrochloride	50458-028	SODIUM HYDROXIDE	2028-01-17

SPRAVATO Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

SPRAVATO's excipient system is simple, low-risk, and commercially important. The nasal spray uses citric acid monohydrate, disodium edetate, sodium chloride, sodium hydroxide, and water for injection to support pH control, chemical stability, tonicity, and product quality. The strongest commercial opportunities are in preservative-free nasal delivery, device-compatible formulation platforms, regional manufacturing, and differentiated esketamine products that improve usability or reduce administration burden.

What excipients are used in SPRAVATO nasal spray?

Each SPRAVATO single-use nasal spray device delivers 28 mg of esketamine hydrochloride, equivalent to 28 mg of esketamine base, in a 0.2 mL aqueous solution. The FDA-approved product contains the following inactive ingredients:

Excipient	Primary formulation role
Citric acid monohydrate	Buffering and pH control
Disodium edetate	Chelation of trace metals and stabilization
Sodium chloride	Tonicity adjustment
Sodium hydroxide	pH adjustment
Water for injection	Aqueous vehicle

The product is preservative-free and supplied in a disposable nasal spray device. The formulation is designed for intranasal administration in a controlled healthcare setting rather than for repeated home use. [1]

The excipient list indicates a conventional aqueous nasal formulation. SPRAVATO does not rely on mucoadhesive polymers, penetration enhancers, volatile cosolvents, surfactants, or antimicrobial preservatives listed in the U.S. prescribing information.

How does the SPRAVATO excipient system support product performance?

Why is citric acid used in SPRAVATO?

Citric acid monohydrate provides buffer capacity and helps maintain the formulation within a pH range compatible with nasal administration and esketamine stability. Nasal formulations require tight pH control because excessive acidity or alkalinity can cause local irritation, alter mucociliary function, and affect drug absorption.

Citric acid is widely used in pharmaceutical products because it is water soluble, commercially available, and supported by extensive toxicology and regulatory precedent. Its inclusion also allows the manufacturer to use sodium hydroxide to fine-tune final pH during manufacturing.

What is the role of disodium edetate?

Disodium edetate, commonly known as disodium EDTA, binds trace metal ions that can catalyze oxidative or other degradation pathways. Chelation is particularly relevant in low-volume aqueous products, where trace metals from raw materials, manufacturing equipment, containers, or the device can affect stability.

Disodium EDTA may also support preservative-free product design by reducing conditions that promote degradation. It does not function as a preservative in the conventional antimicrobial sense.

Why does SPRAVATO contain sodium chloride?

Sodium chloride adjusts osmolality. Nasal products that are substantially hypotonic or hypertonic can increase irritation, run-off, sneezing, or variability in dose retention. Tonicity control is therefore relevant to both tolerability and delivered dose.

The concentration must be balanced against the formulation's pH, drug concentration, container closure system, and spray performance. A generic or follow-on formulation cannot assume that the same nominal sodium chloride level will perform identically in another device.

Why is the product preservative-free?

SPRAVATO is supplied as a single-use device. A single-use presentation reduces the need for antimicrobial preservatives and avoids potential preservative-related irritation. This design is consistent with a controlled administration model in which the patient receives the product at a certified treatment center or under a regulated monitoring process.

A preservative-free formulation also creates a development barrier for competitors. The manufacturer must demonstrate microbiological quality through a combination of sterile or controlled manufacturing, container closure integrity, device performance, and validated handling procedures.

What regulatory requirements apply to SPRAVATO excipients?

The FDA evaluates excipients in the context of the complete drug product, delivery device, route of administration, concentration, manufacturing process, and clinical exposure. An excipient that is acceptable in an oral tablet may require additional justification in an intranasal product.

Key regulatory areas include:

1. Identity, purity, and compendial quality of each excipient.
2. Bioburden and microbial control.
3. Extractables and leachables from the nasal spray device.
4. Container closure integrity.
5. Delivered dose uniformity.
6. Spray pattern, plume geometry, droplet-size distribution, and priming behavior.
7. Nasal irritation and local tolerability.
8. Stability under long-term and accelerated conditions.
9. Compatibility between the formulation and device materials.
10. Control of elemental impurities and degradation products.

The FDA-approved label states that SPRAVATO must be administered under a Risk Evaluation and Mitigation Strategy, or REMS, because of sedation, dissociation, abuse and misuse risks, and potential increases in blood pressure. The REMS affects commercial use of the product but does not eliminate the need for conventional excipient and device controls. [1,2]

What formulation patents and intellectual-property barriers affect SPRAVATO?

SPRAVATO's commercial protection is likely to arise from multiple layers rather than from excipient composition alone.

What is protected by the drug substance and formulation estate?

The relevant protection categories can include:

• Esketamine formulations for intranasal delivery.
• Specific concentration and dose-delivery parameters.
• Nasal spray devices and metered-dose mechanisms.
• Treatment methods for treatment-resistant depression.
• Dosing schedules and maintenance regimens.
• Combination use with oral antidepressants.
• Manufacturing and purification processes for esketamine.
• Stability, packaging, and container closure configurations.

Excipient combinations are often difficult to protect broadly because citric acid, sodium chloride, EDTA, sodium hydroxide, and water are established pharmaceutical materials. A stronger formulation claim would usually require a specific concentration range, pH range, stability result, device interaction, or performance outcome.

Are SPRAVATO excipients listed in the Orange Book?

The Orange Book generally identifies approved drug products and relevant patents that claim the drug substance, drug product, or approved method of use. It does not provide a comprehensive list of every excipient used in an approved medicine.

An excipient combination may support an Orange Book-listed drug-product patent if the patent claims the approved composition or a specific drug-device system. The presence of an excipient in the FDA label does not by itself establish Orange Book protection.

Applicants developing a generic esketamine nasal spray would need to evaluate the current Orange Book patent listings and make the applicable patent certifications, including Paragraph IV certifications where relevant. [3]

When does SPRAVATO lose exclusivity?

SPRAVATO received FDA approval in March 2019 for adults with treatment-resistant depression, in conjunction with an oral antidepressant. It later received approval for depressive symptoms in adults with major depressive disorder accompanied by acute suicidal ideation or behavior, also with an oral antidepressant. In January 2025, the FDA expanded the treatment-resistant depression indication to permit use as monotherapy or with an oral antidepressant. [1,4]

The first approval of a new chemical entity ordinarily provides five years of U.S. drug exclusivity. For a 2019 approval, that statutory period would generally have expired in 2024, subject to applicable regulatory details and any pediatric extension. Patent expiry, litigation, regulatory exclusivity, and FDA approval timing are separate issues. Generic or follow-on entry depends on the remaining enforceable patent claims and the applicant's regulatory pathway.

The practical loss-of-exclusivity risk is therefore determined by:

• Remaining Orange Book-listed patents.
• Patent term adjustments and extensions.
• Any pediatric exclusivity.
• Paragraph IV litigation.
• Approval timing for an abbreviated new drug application.
• The feasibility of reproducing the nasal spray device and formulation.
• Whether the applicant pursues a full NDA rather than an ANDA.

What generic entry risks exist for SPRAVATO?

A generic esketamine nasal spray faces more than an active-ingredient challenge. The main technical barriers are device and product equivalence.

Device equivalence

The applicant must demonstrate consistent delivery of the intended dose. Relevant parameters include:

• Delivered volume per actuation.
• Spray content uniformity.
• Droplet-size distribution.
• Spray plume geometry.
• Priming and repriming behavior.
• Residual volume.
• Orientation sensitivity.
• Performance across temperature and humidity ranges.

A device that delivers the correct average dose but has a different plume or droplet profile could create regulatory and clinical comparability issues.

Formulation equivalence

A follow-on product may need to match or closely control:

• Esketamine concentration.
• pH.
• Osmolality.
• Buffer capacity.
• Viscosity.
• Surface tension.
• Degradation profile.
• Preservative status.
• Container closure compatibility.

Excipient substitution is possible in principle, but each change can affect absorption, tolerability, device function, and stability. A competitor that replaces EDTA, changes the buffer, or introduces a mucoadhesive polymer may face a higher evidentiary burden.

Clinical and safety requirements

Esketamine is a centrally acting drug with dissociation, sedation, blood-pressure, and abuse-related risks. A follow-on applicant must address the clinical and regulatory implications of the route of administration, even if the active ingredient is the same.

The REMS framework also creates a commercial barrier. A generic product may need to operate within an equivalent controlled administration model, which limits the value of simple pharmacy substitution.

Which excipient strategies could create commercial opportunities?

Preservative-free multi-dose nasal systems

A company that develops a validated preservative-free multi-dose platform could offer value in esketamine, naloxone, migraine medicines, vaccines, and peptide products. The main opportunity is not the excipient itself. It is the integrated system comprising microbial control, metering accuracy, container closure, and patient-use reliability.

Improved mucoadhesion and retention

Mucoadhesive excipients could increase nasal residence time and reduce post-administration runoff. Candidate materials may include selected cellulose derivatives, chitosan derivatives, polyacrylic acid systems, and thiolated polymers.

This strategy carries material risks. Increased residence time may increase local exposure, irritation, variability, or systemic absorption. A mucoadhesive formulation could also fall outside the reference product's equivalence profile, pushing development toward a 505(b)(2) NDA rather than an ANDA.

Reduced administration burden

SPRAVATO treatment requires repeated administration and post-dose monitoring. A formulation that improves bioavailability or extends therapeutic effect could reduce the number of devices per visit or the frequency of treatment. Such a product would likely require clinical development and may not qualify as a straightforward generic.

Alternative buffers and low-irritation systems

A competitor could investigate lower-irritation buffer systems, including phosphate, acetate, or alternative citrate concentrations. The commercial value would depend on demonstrated improvement in tolerability, nasal comfort, stability, or absorption.

The claim opportunity would be stronger if the formulation produced a measurable technical effect, such as reduced irritation at equivalent exposure, improved dose retention, or longer shelf life.

Device-integrated formulation platforms

The most defensible commercial opportunity may combine excipient engineering with device engineering. Examples include:

• Dose counters.
• Tamper-evident single-use systems.
• Improved plume control.
• Reduced residual volume.
• Automated administration records.
• Temperature-monitoring packaging.
• Devices designed for use in supervised treatment centers.

Device and formulation claims can reinforce each other when the product's performance depends on their interaction.

How does SPRAVATO compare with other nasal drug products?

Product characteristic	SPRAVATO	Conventional nasal spray	Commercial implication
Active ingredient	Esketamine hydrochloride	Varies	Controlled-substance and CNS risk profile
Dosage form	Aqueous nasal spray	Often aqueous nasal spray	Familiar manufacturing platform
Preservative status	Preservative-free, single-use	Often multi-dose, sometimes preserved	Higher device and microbial-control requirements
Administration	Supervised healthcare setting	Often self-administered	Limits retail substitution value
Excipient complexity	Low to moderate	Low to high	Device performance is central
Clinical monitoring	Required under REMS	Usually not required	Creates operational barriers
Differentiation potential	Formulation, device, dosing, treatment setting	Often price and convenience	Follow-on products need more than lower cost

SPRAVATO differs from long-acting injectable antidepressant strategies because its value depends on rapid intranasal delivery and supervised dosing. It also differs from conventional nasal decongestants and hormone sprays because the safety controls, abuse potential, and clinical monitoring requirements materially affect product design.

What manufacturing and supply-chain barriers affect SPRAVATO excipients?

The individual excipients are generally commodity or well-established pharmaceutical materials. Supply-chain risk is therefore more likely to arise from quality, qualification, and device integration than from scarcity.

Key manufacturing controls include:

• Pharmaceutical-grade citric acid, sodium chloride, and EDTA.
• Low levels of elemental impurities.
• Controlled water quality.
• Consistent pH adjustment.
• Low bioburden.
• Container closure integrity.
• Compatibility with plastics, elastomers, adhesives, and device components.
• Control of extractables and leachables.
• Validated filling and assembly operations.

A supplier with pharmaceutical-grade excipient manufacturing, nasal-delivery experience, and device compatibility data could capture value through qualified alternate-source programs. The strongest opportunity is a dual-source platform that reduces supply interruption risk without changing critical quality attributes.

What licensing opportunities exist around SPRAVATO formulation technology?

Potential licensing targets include:

1. Preservative-free nasal delivery platforms.
2. Mucoadhesive systems with validated intranasal safety.
3. Low-irritation buffering technologies.
4. Metered-dose devices with high delivered-dose uniformity.
5. Nasal formulations that improve esketamine retention.
6. Packaging systems that support supervised administration and chain-of-custody controls.
7. Manufacturing technologies that reduce degradation or improve batch consistency.

A licensee should distinguish between technology that improves SPRAVATO specifically and technology that applies across multiple nasal products. Broad platform value is higher when the excipient system can support CNS drugs, peptides, vaccines, and emergency medicines without requiring extensive reformulation.

How strong is the SPRAVATO excipient patent estate?

The excipient-only estate is likely weaker than the combined formulation, device, method-of-use, and manufacturing estate. Common excipients are difficult to monopolize broadly. Stronger claims would require:

• Narrow concentration ranges.
• Defined pH and osmolality windows.
• A specific esketamine-to-excipient ratio.
• Demonstrated stability advantages.
• Device-dependent delivery characteristics.
• Reduced nasal irritation.
• Improved pharmacokinetic performance.
• A defined treatment regimen.

Freedom-to-operate analysis should separate three questions:

1. Can the proposed formulation use the same or similar excipients?
2. Can the formulation be delivered through a competing nasal device?
3. Can the product be marketed for the same approved indication and dosing schedule?

The answer may differ across the United States, Europe, Japan, China, and other jurisdictions because patent families, regulatory exclusivities, and claim scope vary by country.

Key Takeaways

• SPRAVATO uses a conventional preservative-free aqueous excipient system.
• Citric acid controls pH, disodium EDTA binds trace metals, sodium chloride adjusts tonicity, sodium hydroxide fine-tunes pH, and water for injection is the vehicle.
• The commercial barrier is the integrated formulation-device system, not the individual excipients.
• A generic applicant must address spray performance, formulation equivalence, stability, microbiological control, and the controlled administration environment.
• Excipient-only patents are likely to be narrower than device, method-of-use, formulation, and manufacturing patents.
• The most attractive commercial opportunities are preservative-free nasal platforms, improved retention, lower-irritation formulations, device integration, and qualified alternate-source manufacturing.
• A substantially improved esketamine product may require a 505(b)(2) NDA rather than an ANDA.
• SPRAVATO's 2019 new-chemical-entity exclusivity period has generally expired, but patent and regulatory barriers must be assessed separately.

FAQs

Can a competitor use different excipients in an esketamine nasal spray?

Yes. Different excipients may be used if the applicant satisfies the applicable FDA requirements for safety, quality, performance, and therapeutic equivalence. A material change in absorption, retention, or device performance could require a more extensive NDA pathway.

Is disodium EDTA essential to SPRAVATO?

No public FDA information establishes that disodium EDTA is irreplaceable. It supports control of trace-metal-related degradation, but a substitute would require comparative stability, compatibility, and safety data.

Could a mucoadhesive esketamine spray replace SPRAVATO?

It could be developed as a differentiated product, but mucoadhesion may alter nasal residence time, exposure, tolerability, and pharmacokinetics. The product may not qualify as a simple generic substitute.

Do SPRAVATO excipients create a barrier to biosimilar competition?

No. SPRAVATO is a small-molecule drug, not a biologic. Biosimilar rules do not apply. Competition would proceed through generic or NDA-based pathways, subject to patents, exclusivity, formulation, device, and clinical requirements.

What is the most valuable excipient opportunity in the SPRAVATO market?

The highest-value opportunity is an integrated preservative-free nasal delivery platform that improves dose uniformity, retention, stability, or administration efficiency while remaining compatible with controlled clinical use.

References

1. U.S. Food and Drug Administration. (2025). Spravato (esketamine hydrochloride) nasal spray: Prescribing information. Janssen Pharmaceuticals, Inc.

2. U.S. Food and Drug Administration. (2024). Spravato risk evaluation and mitigation strategy. FDA.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2025, January 16). FDA approves labeling supplement for Spravato to be used as monotherapy for treatment-resistant depression. FDA.